"We will continue with the following principle: if the product is not as good as we wish, we prefer not to sell it or wait until…
In Conversation
"All the healthcare stakeholders, even the government, agree that Lithuania should move the reimbursement criteria from purely cost of the drug to value-based healthcare and e-Health…
"Although we remain relatively small in terms of sales, Brazil has already become a strategic market for Boiron, where some innovative, pilot projects are currently under…
"For Pharmanova, we would like the face of our brand to be someone well-known, well-respected and an everyday user of our products."
The main challenge in the mature markets is the stringency of the regulatory frameworks: the sheer amount of clinical, non-clinical and analytical evidence that is required…
"In Europe, our business model is focused on classical brands and targeted promotion to specialists; a good example having the thrombosis business as one our specialist…
"The government has been trying to implement e-Health capabilities since 2005 but, after more than a decade, they are still far away from the country’s digitalization."
"Brazil is a very competitive market, where all companies invest significant resources to gain market shares."
"PaxVax is basically a fully integrated company. We do everything from research and development, to commercial products, to the supply chain, and also to marketing sales."
"The government offers generous incentives to potential investors, foreigners as well as locals."
"We will focus more of our efforts on the market in Canada, 2018 promises to be the turning year for this."
"Poland is the second largest country globally for AstraZeneca in regard to patient numbers and we are the leader in Poland, a very exciting time for…
